Johnson & Johnson Announces New Grant to Harvard Medical School to Combat Drug-Resistant Tuberculosis
Monday, September 15, 2014
As part of its ongoing commitment to global public health, Johnson & Johnson today announced its affiliate Janssen Pharmaceutica NV (Janssen) has entered into a novel collaboration with Harvard Medical School to address critical gaps in the global struggle against tuberculosis (TB). Janssen is providing a grant to the renowned medical school to support a two-year research, policy, and advocacy program to improve access to TB diagnosis and treatment for the world’s most vulnerable communities, with a particular focus on drug-resistant TB (DR-TB) and TB in children.
According to the latest data from the World Health Organization, an estimated 450,000 people developed DR-TB in 2012, and an estimated 170,000 people died from the disease. In addition, the results of a recent study conducted by Harvard Medical School revealed that one million children suffer from TB each year – twice the number previously thought to have TB and three times the number of children that are diagnosed. Researchers estimated that 32,000 of these children suffer from DR-TB each year.
Source: Press release (link opens in a new window)
- Education, Health Care